drugset / Trial / NCT00586911
Betaine in Patients With Nonalcoholic Steatohepatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
Timeline
- Start
- 2003-01
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Betaine | Small molecule | 20 mg | — |